Motexafin lutetium

Motexafin lutetium
Names
Other names
Antrin; Lu texaphyrin; Lu-Tex; Lutetium texaphyrin; Lutrin; Optrin; PCI 0123
Identifiers
3D model (JSmol)
ChemSpider
DrugBank
UNII
  • InChI=1S/C48H66N5O10.2C2H4O2.Lu.H2O/c1-7-35-36(8-2)40-28-42-38(12-10-14-55)34(4)46(53-42)32-50-44-30-48(63-26-24-61-22-20-59-18-16-57-6)47(62-25-23-60-21-19-58-17-15-56-5)29-43(44)49-31-45-33(3)37(11-9-13-54)41(52-45)27-39(35)51-40;2*1-2(3)4;;/h27-32,54-55H,7-26H2,1-6H3;2*1H3,(H,3,4);;1H2/q-1;;;+3;/p-2
    Key: WIQKYZYFTAEWBF-UHFFFAOYSA-L
  • CC([O-])=O.CCC1=C2[N-]C(/C=C3N=C(/C=N/C4=CC(OCCOCCOCCOC)=C(OCCOCCOCCOC)C=C4/N=C/C(C(C)=C/5CCCO)=[N]([Lu+3])C5=C/2)C(C)=C\3CCCO)=C1CC
Properties
C52H72LuN5O14
Molar mass 1166.136 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
checkY verify (what is checkYX markN ?)

Motexafin lutetium is a texaphyrin, developed by Pharmacyclics Inc. (proposed trade names Lutrin, Antrin and Optrin)

It is a photosensitiser for use in photodynamic therapy to treat skin conditions and superficial cancers.

It has also been tested for use in photoangioplasty (photodynamic treatment of diseased arteries).

It is photoactivated by 732 nm light which allows greater depth of penetration.

Clinical trials

Phase II clinical trials were in progress in 1999.

A phase I trial for prostate cancer reported in 2009.

As of 2017, this drug is no longer being developed.

See also

References

  1. ↑ Pharmacyclics Announces Final Phase 1 Results of Antrin Phototherapy For Coronary Artery Disease Archived 2011-07-16 at the Wayback Machine, 2002
  2. ↑ O'Connor, Aisling E; Gallagher, William M; Byrne, Annette T (September 2009). "Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy". Photochemistry and Photobiology.
  3. ↑ Antrin Photoangioplasty Phase II Clinical Trial Patient Treated During Live Case Demonstration at TCT Deprecated link archived 2012-07-13 at archive.today, 1999
  4. ↑ Patel, H; Mick, R; Finlay, J; Zhu, TC; Rickter, E; Cengel, KA; Malkowicz, SB; Hahn, SM; Busch, TM (2008). "Motexafin lutetium-photodynamic therapy of prostate cancer: Short and long term effects on PSA". Clinical Cancer Research. 14 (15): 4869–76. doi:10.1158/1078-0432.CCR-08-0317. PMC 2680073. PMID 18676760.
  5. ↑ Kirkpatrick, DL; Powis, Garth (2017). "Clinically Evaluated Cancer Drugs Inhibiting Redox Signaling". Antioxidants & Redox Signaling. 26 (6): 262–273. doi:10.1089/ars.2016.6633. PMC 5312618. PMID 26983373.